| ViraEpi4832 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1367 | 1367 | No methylation | 0% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4833 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1408 | 1408 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4834 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1410 | 1410 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4835 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1415 | 1415 | No methylation | 0% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4836 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1428 | 1428 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4837 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1433 | 1433 | No methylation | 0% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4838 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1436 | 1436 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4839 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1439 | 1439 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4840 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1451 | 1451 | No methylation | 0% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4841 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1455 | 1455 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4842 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1465 | 1465 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4843 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1471 | 1471 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4844 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1486 | 1486 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4845 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1498 | 1498 | Hypo | 25% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4846 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1505 | 1505 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4847 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1510 | 1510 | Hypo | 16.66% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4848 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1514 | 1514 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 | | ViraEpi4849 | Hepatitis B virus (HBV) | Enhancer II | CpG Island II | 1520 | 1520 | Hypo | 8.33% | Liver tissue samples | NA | 12 patients | Hepatocellular carcinoma (HCC) | BS-PCR | 26000761 |